Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis von Ruzicka, Thomas, Hanifin, Jon M, Furue, Masutaka, Pulka, Grazyna, Mlynarczyk, Izabela, Wollenberg, Andreas, Galus, Ryszard, Etoh, Takafumi, Mihara, Ryosuke, Yoshida, Hiroki, Stewart, Jonathan, Kabashima, Kenji

Volltext

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study von Kabashima, Kenji, Furue, Masutaka, Hanifin, Jon M., Pulka, Grazyna, Wollenberg, Andreas, Galus, Ryszard, Etoh, Takafumi, Mihara, Ryosuke, Nakano, Miwa, Ruzicka, Thomas

Volltext

Photocytotoxicity studies of polyamidoamine (PAMAM) dendrimer and its glucoheptoamidated derivative as delivery drug systems in local PUVA photochemotherapy von Borowska, Katarzyna, Radej, Sebastian, Galus, Ryszard, Śladowski, Dariusz, Paskal, Wiktor, Mehlich, Dawid, Wołowiec, Stanisław

Volltext

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial von Eichenfield, Lawrence F, Flohr, Carsten, Sidbury, Robert, Siegfried, Elaine, Szalai, Zsuzsanna, Galus, Ryszard, Yao, Zhirong, Takahashi, Hidetoshi, Barbarot, Sébastien, Feeney, Claire, Zhang, Fan, DiBonaventura, Marco, Rojo, Ricardo, Valdez, Hernan, Chan, Gary

Volltext

Molecular Implications of Skin Lesions in Tuberous Sclerosis von JOZWIAK, Jaroslaw, GALUS, Ryszard

Volltext

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis von Bieber, Thomas, Simpson, Eric L, Silverberg, Jonathan I, Thaçi, Diamant, Paul, Carle, Pink, Andrew E, Kataoka, Yoko, Chu, Chia-Yu, DiBonaventura, Marco, Rojo, Ricardo, Antinew, Jeremias, Ionita, Ileana, Sinclair, Rodney, Forman, Seth, Zdybski, Jacek, Biswas, Pinaki, Malhotra, Bimal, Zhang, Fan, Valdez, Hernan

Volltext

51573 Dupilumab Treatment for up to 5 Years Improves Eczema Area and Severity Index Score Across all Anatomical Regions in Adults With Moderate-to-Severe Atopic Dermatitis von Bissonnette, Robert, Beck, Lisa A., Deleuran, Mette, Nakahara, Takeshi, Galus, Ryszard, Chen, Zhen, Avetisova, Elena, Dubost-Brama, Ariane, Shabbir, Arsalan

Volltext

Long-Term Efficacy Of Dupilumab In Adults With Moderate-to-Severe Atopic Dermatitis: Results From A 5-Year Open-Label Extension Trial von Beck, Lisa, Bissonnette, Robert, Deleuran, Mette, Nakahara, Takeshi, Galus, Ryszard, Xiao, Jing, Avetisova, Elena, Dubost-Brama, Ariane, Shabbir, Arsalan

Volltext

Coexistence of psoriasis and atopic dermatitis von Terlikowska-Brzósko, Agnieszka, Paluchowska, Elwira, Owczarek, Witold, Koktysz, Robert, Galus, Ryszard

Volltext

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo von Rosmarin, David, Passeron, Thierry, Pandya, Amit G., Grimes, Pearl, Harris, John E., Desai, Seemal R., Lebwohl, Mark, Ruer-Mulard, Mireille, Seneschal, Julien, Wolkerstorfer, Albert, Kornacki, Deanna, Sun, Kang, Butler, Kathleen, Ezzedine, Khaled

Volltext

52680 Long-Term Safety Data for Dupilumab in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis von Bissonnette, Robert, Beck, Lisa A., Deleuran, Mette, Nakahara, Takeshi, Galus, Ryszard, Coleman, Anna, Gherardi, Guy, Xiao, Jing, Avetisova, Elena, Dubost-Brama, Ariane, Shabbir, Arsalan

Volltext

52697 Incidence of Injection-Site Reactions With Dupilumab Treatment in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis von Bissonnette, Robert, Beck, Lisa A., Deleuran, Mette, Nakahara, Takeshi, Galus, Ryszard, Coleman, Anna, Gherardi, Guy, Chen, Zhen, Avetisova, Elena, Dubost-Brama, Ariane, Shabbir, Arsalan

Volltext

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis von Beck, Lisa A., Deleuran, Mette, Bissonnette, Robert, de Bruin-Weller, Marjolein, Galus, Ryszard, Nakahara, Takeshi, Seo, Seong Jun, Khokhar, Faisal A., Vakil, Jignesh, Xiao, Jing, Marco, Ainara Rodriguez, Levit, Noah A., O’Malley, John T., Shabbir, Arsalan

Volltext

The RAGE Pathway in Skin Pathology Development: A Comprehensive Review of Its Role and Therapeutic Potential von Radziszewski, Marcin, Galus, Ryszard, Łuszczyński, Krzysztof, Winiarski, Sebastian, Wąsowski, Dariusz, Malejczyk, Jacek, Włodarski, Paweł, Ścieżyńska, Aneta

Volltext

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study von Beck, Lisa A, Bissonnette, Robert, Deleuran, Mette, Nakahara, Takeshi, Galus, Ryszard, Coleman, Anna, Gherardi, Guy, Xiao, Jing, Dingman, Robert, Xu, Christine, Avetisova, Elena, Dubost-Brama, Ariane, Shabbir, Arsalan

Volltext

Human Beta Defensin-2 mRNA and Proteasome Subunit β Type 8 mRNA Analysis, Useful in Differentiating Skin Biopsies from Atopic Dermatitis and Psoriasis Vulgaris Patients von Terlikowska-Brzósko, Agnieszka, Galus, Ryszard, Murawski, Piotr, Niderla-Bielińska, Justyna, Młynarczuk-Biały, Izabela, Paluchowska, Elwira, Owczarek, Witold

Volltext

Novel diagnostic and prognostic factors for the advanced melanoma based on the glycosylation-related changes studied by biophysical profiling methods von Sobiepanek, Anna, Kowalska, Patrycja D., Szota, Magdalena, Grzywa, Tomasz M., Nowak, Jakub, Włodarski, Paweł K., Galus, Ryszard, Jachimska, Barbara, Kobiela, Tomasz

Volltext

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years von Thyssen, Jacob P., Blauvelt, Andrew, Lockshin, Benjamin, Galus, Ryszard, Lynde, Charles, Xiao, Jing, Levit, Noah A., Marco, Ainara Rodríguez, Shabbir, Arsalan

Volltext

417 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years von Beck, Lisa A, Bissonnette, Robert, Deleuran, Mette , Nakahara, Takeshi, Galus, Ryszard , Khokhar, Faisal A, Coleman, Anna , Gherardi, Guy, Xiao, Jing, Dingman, Robert , Xu, Christine, Avetisova, Elena, Dubost-Brama, Ariane, Shabbir, Arsalan 

Volltext

416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years von Beck, Lisa A, Bissonnette, Robert, Deleuran, Mette , Nakahara, Takeshi, Galus, Ryszard , Khokhar, Faisal A, Coleman, Anna , Gherardi, Guy , Xiao, Jing, Dingman, Robert , Xu, Christine, Avetisova, Elena , Dubost-Brama, Ariane, Shabbir, Arsalan

Volltext